Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)

Next Previous
Trial Profile

A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Hepatorenal syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms CONFIRM
  • Sponsors Mallinckrodt Inc.; Mallinckrodt plc

Most Recent Events

  • 30 Oct 2024 According to Mallinckrodt plc media release, poster highlighting analysis of the study were presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) taking place in San Diego from November 15-19, 2024.
  • 22 Jan 2024 According to Mallinckrodt plc media release, data of post hoc analysis of this trial will be presented at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress,
  • 22 Jan 2024 Results of a post hoc analysis of the Phase 3 CONFIRM trial published in the Mallinckrodt plc Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top